Misplaced Pages

Lumacaftor: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 10:41, 9 December 2022 editAlyInWikiWonderland (talk | contribs)Autopatrolled, Extended confirmed users81,801 editsNo edit summary← Previous edit Revision as of 13:20, 28 March 2024 edit undoKimen8 (talk | contribs)Extended confirmed users5,112 edits Changing short description from "Pharmaceutical drug used to treat cystic fibrosis" to "Cystic fibrosis drug"Tag: Shortdesc helperNext edit →
Line 1: Line 1:
{{short description|Pharmaceutical drug used to treat cystic fibrosis}} {{Short description|Cystic fibrosis drug}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed

Revision as of 13:20, 28 March 2024

Cystic fibrosis drug Pharmaceutical compound
Lumacaftor
Clinical data
Other namesVX-809
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • 3-{6-{amino}-3-methylpyridin-2-yl}benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.241.800 Edit this at Wikidata
Chemical and physical data
FormulaC24H18F2N2O5
Molar mass452.414 g·mol
3D model (JSmol)
SMILES
  • CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
InChI
  • InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
  • Key:UFSKUSARDNFIRC-UHFFFAOYSA-N
  (what is this?)  (verify)

Lumacaftor (VX-809) is a pharmaceutical drug that acts as a chaperone during protein folding and increases the number of CFTR proteins that are trafficked to the cell surface. It is available in a single pill with ivacaftor; the combination, lumacaftor/ivacaftor (brand name Orkambi), is used to treat people with cystic fibrosis who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the defective protein that causes the disease. It was developed by Vertex Pharmaceuticals and the combination was approved by the FDA in 2015. As of 2015, lumacaftor had no medical use on its own.

See also

  • Ataluren, targeting premature stop codons

References

  1. ^ Kuk K, Taylor-Cousar JL (December 2015). "Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 9 (6): 313–26. doi:10.1177/1753465815601934. PMID 26416827.
  2. Lumacaftor label. Last updated July 2015. Check index page here for label updates
  3. "Orkambi (lumacaftor and ivacaftor)". CenterWatch. Retrieved 24 March 2016.
Other respiratory system products (R07)
Lung surfactants
Respiratory stimulants
5-HT4 receptor agonists
Other agents for treating respiratory depression
Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: